Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,081 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704).
Kurokawa Y, Doki Y, Kitabayashi R, Yoshikawa T, Nomura T, Tsuji K, Goto M, Cho H, Hihara J, Hiki N, Nunobe S, Mizusawa J, Boku N, Terashima M. Kurokawa Y, et al. Among authors: cho h. Gastric Cancer. 2024 Mar;27(2):366-374. doi: 10.1007/s10120-023-01453-7. Epub 2024 Jan 5. Gastric Cancer. 2024. PMID: 38180622 Free PMC article. Clinical Trial.
English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology.
Hirota S, Tateishi U, Nakamoto Y, Yamamoto H, Sakurai S, Kikuchi H, Kanda T, Kurokawa Y, Cho H, Nishida T, Sawaki A, Ozaka M, Komatsu Y, Naito Y, Honma Y, Takahashi F, Hashimoto H, Udo M, Araki M, Nishidate S; Members of the Systematic Review Team of the Present Guidelines. Hirota S, et al. Among authors: cho h. Int J Clin Oncol. 2024 Jun;29(6):647-680. doi: 10.1007/s10147-024-02488-1. Epub 2024 Apr 13. Int J Clin Oncol. 2024. PMID: 38609732 Free PMC article.
Albumin-Globulin Ratio Is an Independent Prognostic Factor for Gastric Cancer Patients who Received Curative Treatment.
Fukuda M, Aoyama T, Hashimoto I, Maezawa Y, Kato A, Hara K, Kazama K, Komori K, Tamagawa A, Cho H, Ishiguro T, Segami K, Nakazono M, Otani K, Sawazaki S, Numata M, Kawahara S, Oshima T, Saito A, Yukawa N, Rino Y. Fukuda M, et al. Among authors: cho h. In Vivo. 2024 Mar-Apr;38(2):904-910. doi: 10.21873/invivo.13517. In Vivo. 2024. PMID: 38418138 Free PMC article.
Geriatric Nutritional Risk Index Is an Independent Prognostic Factor for Patients With Esophageal Cancer Who Receive Curative Treatment.
Kato A, Aoyama T, Maezawa Y, Hashimoto I, Hara K, Kazama K, Numata M, Sawazaki S, Tamagawa A, Cho H, Morita J, Tanabe M, Kamiya N, Tamagawa H, Otani K, Kawahara S, Oshima T, Yukawa N, Saito A, Rino Y. Kato A, et al. Among authors: cho h. Anticancer Res. 2024 Jan;44(1):331-337. doi: 10.21873/anticanres.16816. Anticancer Res. 2024. PMID: 38159974
Pretreatment Fibrinogen Level Is a Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment.
Aoyama T, Kato A, Hashimoto I, Maezawa Y, Hara K, Kawahara S, Kazama K, Komori K, Yoshizawa S, Tamagawa A, Tateishi M, Minami T, Cho H, Morita J, Otani K, Sawazaki S, Numata M, Tanabe M, Oshima T, Saito A, Yukawa N, Rino Y. Aoyama T, et al. Among authors: cho h. Anticancer Res. 2024 Jan;44(1):249-255. doi: 10.21873/anticanres.16808. Anticancer Res. 2024. PMID: 38159985
Lymphocyte to Monocyte Ratio Is an Independent Prognostic Factor in Patients With Esophageal Cancer Who Receive Curative Treatment.
Aoyama T, Kato A, Maezawa Y, Hashimoto I, Hara K, Komori K, Kawahara S, Numata M, Kazama K, Sawazaki S, Kamiya N, Yoshizawa S, Otani K, Tamagawa A, Cho H, Tamagawa H, Oshima T, Yukawa N, Saito A, Rino Y. Aoyama T, et al. Among authors: cho h. Anticancer Res. 2024 Jan;44(1):339-346. doi: 10.21873/anticanres.16817. Anticancer Res. 2024. PMID: 38159996
CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment.
Aoyama T, Hashimoto I, Maezawa Y, Hara K, Kazama K, Komori K, Numata M, Tamagawa A, Fukuda M, Cho H, Morita J, Yoshizawa S, Otani K, Kato A, Tanabe M, Nakazono M, Kawahara S, Oshima T, Saito A, Yukawa N, Rino Y. Aoyama T, et al. Among authors: cho h. Anticancer Res. 2024 Feb;44(2):815-822. doi: 10.21873/anticanres.16873. Anticancer Res. 2024. PMID: 38307573
What kind of tumour rupture requires adjuvant therapy?
Chiguchi G, Cho H. Chiguchi G, et al. Among authors: cho h. Br J Cancer. 2024 Oct;131(7):1109-1110. doi: 10.1038/s41416-024-02812-6. Epub 2024 Aug 27. Br J Cancer. 2024. PMID: 39191892 No abstract available.
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.
Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K, Yajima S, Yashiro M, Yokoi K, Cho H, Ehira T, Nakahara K, Yasuda H, Isobe K, Hayashida T, Hatakeyama S, Akakura K, Aoki D, Nomura H, Tada Y, Yoshimatsu Y, Miyachi H, Takebayashi C, Hanamura I, Takahashi H. Kikuchi Y, et al. Among authors: cho h. Int J Clin Oncol. 2024 May;29(5):512-534. doi: 10.1007/s10147-024-02497-0. Epub 2024 Mar 17. Int J Clin Oncol. 2024. PMID: 38493447
13,081 results
You have reached the last available page of results. Please see the User Guide for more information.